PTC Therapeutics Overview
- Founded
-
1998
- Status
-
Public
- Employees
-
1,410
- Stock Symbol
-
PTCT
- Investments
-
7
- Share Price
-
$43.50
- (As of Thursday Closing)
PTC Therapeutics General Information
Description
PTC Therapeutics Inc is a biopharmaceutical company focused on the discovery, development, and commercialization of orally administered, small-molecule therapeutics. Its target area is RNA biology post-transcriptional control processes of the events occurring in a cell when an RNA messenger is copied from DNA during the transcription process. The discovered products address multiple therapeutic areas, including rare disorders, such as nonsense mutations in Duchenne muscular dystrophy and oncology.
Contact Information
- 100 Corporate Court
- South Plainfield, NJ 07080-2449
- United States
PTC Therapeutics Stock Performance
(As of Thursday Closing)
| Stock Price | Previous Close | 52 wk Range | Market Cap | Shares | Average Volume | EPS |
|---|---|---|---|---|---|---|
| $43.50 | $41.93 | $25.01 - $59.84 | $3.11B | 74.2M | 880K | -$7.89 |
PTC Therapeutics Financials Summary
|
In Thousands, USD |
TTM 31-Mar-2023 | FY 2022 31-Dec-2022 | FY 2021 31-Dec-2021 | FY 2020 31-Dec-2020 |
|---|---|---|---|---|
| EV | 3,868,528 | 2,912,139 | 2,483,493 | 3,437,771 |
| Revenue | 770,447 | 698,801 | 538,593 | 380,766 |
| EBITDA | (360,552) | (367,762) | (368,184) | (303,090) |
| Net Income | (571,250) | (559,017) | (523,901) | (438,160) |
| Total Assets | 1,608,839 | 1,705,619 | 1,938,056 | 2,208,278 |
| Total Debt | 701,172 | 703,627 | 535,379 | 420,438 |
PTC Therapeutics Valuation & Funding
| Deal Type | Date | Amount | Valuation/ EBITDA |
Post-Val | Status | Debt |
|---|
PTC Therapeutics Comparisons
Industry
Financing
Details
000000
000000
PTC Therapeutics Competitors (73)
| Company Name | Financing Status | Location | Employees | Total Raised | Last Financing Date/Type | Last Financing Amount |
|---|---|---|---|---|---|---|
| Bluebird Bio | Formerly VC-backed | Somerville, MA | 000 | 00000 | 000000000 | 00000 |
| 0000000000 0000000 | Formerly VC-backed | Novato, CA | 0000 | 00000 | 000000000 | 00000 |
| 0000000 0000000000 | Formerly VC-backed | La Jolla, CA | 000 | 00000 | 00000000 | 00000 |
| 000000000 00000000 | Corporation | Pasadena, CA | 000 | 00.000 | 000000 - 000 | 00.000 |
| 0000000 0000000000 | Formerly VC-backed | Cambridge, MA | 0000 | 00.000 | 0000 | 00.000 |
PTC Therapeutics Patents
PTC Therapeutics Recent Patent Activity
| Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
|---|---|---|---|---|---|
| US-20220151938-A1 | Tablet for use in treating huntington's disease and method of making the same | Pending | 28-Jan-2022 | 000000000 | 0 |
| AU-2021379692-A1 | Tablet for use in treating huntington's disease and method of making the same | Pending | 12-Nov-2021 | ||
| AU-2021380758-A1 | Novel rna transcript | Pending | 11-Nov-2021 | ||
| US-20230022538-A1 | Pharmaceutical compositions comprising 2,3,5-trimethyl-6-nonylcyclohexa-2,5-diene-1,4-dione | Pending | 08-Jul-2021 | 0000000000 | |
| US-20220162610-A1 | Novel rna transcript | Pending | 12-Nov-2020 | C12N15/63 | 0 |
PTC Therapeutics Executive Team (30)
PTC Therapeutics Board Members (22)
| Name | Representing | Role | Since |
|---|---|---|---|
| Alethia Young | Self | Board Member | 000 0000 |
| Allan Jacobson Ph.D | Self | Founder & Board Member | 000 0000 |
| David Southwell | Self | Board Member | 000 0000 |
| Emma Reeve | Self | Board Member | 000 0000 |
| Eric Jacobsen Ph.D | PTC Therapeutics | Board Member | 000 0000 |
PTC Therapeutics Signals
Growth Rate
Growth
Size Multiple
Key Data Points
Twitter Followers
5.5k
Similarweb Unique Visitors
15.0K
Majestic Referring Domains
314
PTC Therapeutics Investors
| Investor Name | Investor Type | Holding | Investor Since | Participating Rounds | Contact Info |
|---|
PTC Therapeutics Investments & Acquisitions (7)
| Company Name | Deal Date | Deal Type | Deal Size | Industry | Lead Partner |
|---|---|---|---|---|---|
| 0000 0000000 | 31-Oct-2022 | 00000 0000 | Drug Discovery | ||
| 00000 0000000 | 29-May-2020 | 0000000000 | 00000 | Biotechnology | 000000 00 |
| 00000000000 0 | 29-Oct-2019 | 000000000 | Buildings and Property | ||
| 00000000000 0 | 25-Oct-2019 | 0000000000 | 00000 | Biotechnology | |
| ClearPoint Neuro | 17-May-2019 | PIPE | 00.000 | Surgical Devices | 000000 00 |
PTC Therapeutics ESG
Risk Overview
Risk Rating
Updated December, 02, 2022
23.33 | Med Risk
Risk Scale
A lower score indicates better sustainability
Negl
0-10
Low
10-20
Med
20-30
High
30-40
Severe
40+
Exposure
Exposure refers to the extent to which a company is exposed to different material ESG issues
00.0
Management
Management is related to actions taken to manage ESG issues
00.00
Peers Analysis
Peer performance insights compare the company’s ESG performance to the performance of selected peers to help inform future ESG decisions and drive internal performance improvements.
Global
Covered Companies
00 of 15,233
Rank
Percentile
Pharmaceuticals
Industry
00 of 866
Rank
Percentile
Biotechnology
Subindustry
00 of 382
Rank
Percentile
